Sunday, February 3, 2008

Looks like Rummy's stock dividends will be slightly lower

Recall, we've mentioned Rummy's ties to Gilead Sciences? Check this out:
"Doctors Without Borders is reporting that four patents for tenofovir disoproxil fumarate, a key AIDS/HIV drug, have been revoked on grounds of prior art. This is potentially good news for India & Brazil who need this drug to be cheap; if the US action leads to the patent being rejected in these countries, competition could drastically lower prices. But the ruling bad news for Gilead Sciences. The company has vowed to appeal. We discussed this drug before."
If you follow that last link, you'll understand the importance of this for those exposed to HIV:
"The drugs are tenofovir (Viread) and emtricitabine, or FTC (Emtriva), sold in combination as Truvada by Gilead Sciences Inc., a California company best known for inventing Tamiflu, a drug showing promise against bird flu. Unlike vaccines, which work through the immune system -- the very thing HIV destroys -- AIDS drugs simply keep the virus from reproducing. They already are used to prevent infection in health care workers accidentally exposed to HIV, and in babies whose pregnant mothers receive them."
Remember, Gilead Sciences plans to appeal the ruling, so this isn't a done deal yet.

No comments:

Post a Comment